Castle Biosciences, Inc. - Common stock (NQ:CSTL)

39.10 -0.02 (-0.05%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Price and Volume

Volume	218,595
Open	39.17
Bid (Size)	35.79 (200)
Ask (Size)	43.00 (500)
Prev. Close	39.12
Today's Range	38.98 - 39.58
52wk Range	14.59 - 40.61
Shares Outstanding	25,167,365
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

November 17, 2025

Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development

From Castle Biosciences, Inc.

Via GlobeNewswire

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

November 14, 2025

Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor...

From Castle Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	+39.4%	+39.4%
1 Month	+50.4%	+50.4%
3 Month	+61.5%	+61.5%
6 Month	+140.3%	+140.3%
1 Year	+24.5%	+24.5%

More News

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

November 11, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Why Castle Biosciences' Rally Might Just Be Getting Started ↗

November 05, 2025

Via Benzinga

AMD To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 05, 2025

Via Benzinga

Castle Biosciences Reports Third Quarter 2025 Results

November 03, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

November 03, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

A Glimpse of Castle Biosciences's Earnings Potential ↗

October 31, 2025

Via Benzinga

Castle Biosciences to Participate in Upcoming Investor Conferences

October 28, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

October 26, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

October 24, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

October 13, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

October 01, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

September 23, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

September 17, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

September 09, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

August 25, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences to Participate in Upcoming Investor Conferences

August 21, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Here are the top movers in Tuesday's session. ↗

August 05, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 05, 2025

Via Benzinga

Tuesday's session: top gainers and losers ↗

August 05, 2025

Via Chartmill

Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday ↗

August 05, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

August 05, 2025

Via Chartmill

These stocks are moving in today's pre-market session ↗

August 05, 2025

Via Chartmill

Frequently Asked Questions

Is Castle Biosciences, Inc. - Common stock publicly traded?

Yes, Castle Biosciences, Inc. - Common stock is publicly traded.

What exchange does Castle Biosciences, Inc. - Common stock trade on?

Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Castle Biosciences, Inc. - Common stock?

The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market

What is the current price of Castle Biosciences, Inc. - Common stock?

The current price of Castle Biosciences, Inc. - Common stock is 39.10

When was Castle Biosciences, Inc. - Common stock last traded?

The last trade of Castle Biosciences, Inc. - Common stock was at 12/02/25 04:00 PM ET

What is the market capitalization of Castle Biosciences, Inc. - Common stock?

The market capitalization of Castle Biosciences, Inc. - Common stock is 984.04M

How many shares of Castle Biosciences, Inc. - Common stock are outstanding?

Castle Biosciences, Inc. - Common stock has 984M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.